INVA vs NVS
INVA: Innoviva is a diversified pharmaceutical holding company managing a portfolio of respiratory royalty assets and specialty medicine operations. NVS: Novartis is a leading global pharmaceutical company focused on discovering and developing innovative, high-efficacy medicines across oncology, immunology, and neuroscience.
Side-by-side fundamentals
| Metric | INVA | NVS | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $21.28 | $153.64 | |
| Market cap | $1.5B | $286.6B | |
| P/E as of 2026-10-20 | 4.94 (earnings are mostly non-operating: 61% of trailing pre-tax income, to 2026-06-30) | n/a | |
| Net margin FY2025, SEC XBRL | +65.9% | n/a | |
| Gross margin FY2025, SEC XBRL | +74.8% | n/a | |
| Operating margin FY2025, SEC XBRL | +39.8% | n/a | |
| ROE FY2025, SEC XBRL | +23.1% | +30.0% | NVS higher |
| ROA FY2025, SEC XBRL | +16.6% | +12.6% | INVA higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.21 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +14.7% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +7.5% | n/a | |
| Dividend yield as of 2026-09-03 | n/a | +3.4% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-02 | 0.14 | 0.22 | |
| 1-year return as of 2026-10-20 close | +23.6% | +16.6% | INVA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.